Imatinib is a tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, …

Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents a BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid leukemia (CML). Imatinib …

Feb 1, 2026 · The mechanism of action of imatinib is characterized by high specificity and is directly tied to the molecular pathogenesis of the diseases it treats. It functions as a competitive inhibitor at the …

Imatinib works by stopping the Bcr-Abl tyrosine-kinase. This can slow growth or result in programmed cell death of certain types of cancer cells. [2] Imatinib was approved for medical use in the United …

Imatinib binds to the BCR-ABL protein and inhibits its activity [Articles: 12755554, 13679030, 16122278, 11287972]. This results in inhibition of proliferation and induction of apoptosis in BCR-ABL-positive …

Imatinib caused dose-dependent inhibition of proliferation in C2 canine mastocytoma cells with IC50 of 269+/- 180 nM, and growth-inhibitory effects were associated with cell-cycle arrest and apoptosis …

Aug 24, 2012 · Imatinib is a potent competitive inhibitor of ATP binding to Abl kinase, as well as to the c-Kit and PDGF receptor tyrosine kinases.

Nov 12, 2025 · In general, the therapeutic action of IMT has been linked to its direct effects on tumor cells harboring oncogenic kinases or through inhibition of cellular kinases involved in pathogenic …

Its primary mechanism of action involves the competitive inhibition of the ATP-binding site of the BCR-Abl tyrosine kinase, the constitutively active oncoprotein responsible for the pathogenesis of Chronic …

MECHANISM OF ACTION: Imatinib inhibits BCR-ABL tyrosine kinase, the fusion protein created by the Philadelphia chromosome abnormality that characterizes chronic myeloid leukemia.